Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 1, 2002, Pages 9-16

  Gilliland, D Gary ^a   Gribben, John G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Autologous stem cell transplantation; Cytogenetics; Interphase FISH; Loss of heterozygosity; Non Hodgkin's lymphoma; Point mutation; Therapy related MDS AML; X activation based clonality assays

Indexed keywords

B LYMPHOCYTE ANTIBODY; COMPLEMENT; CYCLOPHOSPHAMIDE; ETHYLNITROSOUREA; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD DISEASE; CAUSE OF DEATH; CELL CLONING; CELL PROLIFERATION; CELL SURVIVAL; CYTOGENETICS; DISEASE COURSE; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MALE; MORBIDITY; MYELODYSPLASTIC SYNDROME; POINT MUTATION; POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SOMATIC MUTATION; STEM CELL TRANSPLANTATION; X CHROMOSOME INACTIVATION; AUTOTRANSPLANTATION; GENETICS; METHODOLOGY; MUTATION; PATHOLOGY; RISK FACTOR; SECOND CANCER;

HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036167066     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm11846355     Document Type: Article

References (39)

1. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
2. Myelodysplastic syndrome after autologous transplantation for lymphoma: The price of progress
3. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
4. Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma
5. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure
6. Secondary or therapy-related MDS and AML and their chromosome aberrations: Important to study but difficult to establish causality
7. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma
8. Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT Lymphoma and Late Effects Working Parties
9. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
10. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse
11. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study
12. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
13. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
14. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
15. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
16. Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukemia: A case report and cell lineage study
17. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: A single institution study
18. Malignant neoplasms following bone marrow transplantation
19. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
20. Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas
21. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV)
22. Functional characterization of TEL/AML1 fusion protein in the regulation of human CR1 gene promoter
23. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia
24. The fusion gene Cbfβ blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukemia
25. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences
26. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice
27. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice
28. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis
29. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia
30. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals
31. BCL2 translocation frequency rises with age in humans
32. Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay
33. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases
34. Quantification of t(14;18) in the lymphocytes of healthy adult humans as a possible biomarker for environmental exposures to carcinogens
35. Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals
36. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
37. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors
38. Myelodysplastic syndrome occurring after autologous bone marrow transplantation for lymphoma. Morphologic features
39. New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis